Vermillion's Q4 Loss Widens, Revenues Fall in Anticipation of Dx Launch | GenomeWeb
NEW YORK (GenomeWeb News) – Vermillion yesterday reported minimal revenues for the fourth quarter of 2007, accompanied by a wider net loss, as it continues to take steps to launch its first diagnostic tests later this year.
 
Vermillion reiterated in its financial report that it “anticipates no major revenue until its diagnostic tests are commercialized” due to the sale of its proteomics tools business to Bio-Rad in November 2006.  
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.